Athersys receives stem cell trial approval in U.K. Athersys announced that the Medicines and Healthcare products Regulatory Agency has approved Athersys' application to expand its ongoing Phase 2 study evaluating the administration of MultiStem therapy to patients who have suffered an ischemic stroke. Enrollment at United Kingdom sites is expected to commence following final Ethics Committee review and the completion of final preparations at participating clinical centers. "The MHRA authorization will enable us to bring several leading United Kingdom stroke centers into the study, which will help us to speed the completion of the stroke clinical trial," said Dr. Gil Van Bokkelen, chairman and CEO of Athersys. "The authorization is also noteworthy as it marks the initiation of MultiStem clinical development activity in the United Kingdom."
News For ATHX From The Last 14 Days
Check below for free stories on ATHX the last two weeks.